Last reviewed 2026-04-20 · How we verify

MTPI

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction (PHASE4)
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (PHASE1)
• Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (PHASE1)
• Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine (PHASE4)
• Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (PHASE1)
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (PHASE1,PHASE2)
• Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer (PHASE1)
• Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) (PHASE1,PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MTPI CI brief — competitive landscape report
• MTPI updates RSS · CI watch RSS
• The University of Texas Health Science Center, Houston portfolio CI